title: [The efficiency of influenza vaccines in patients with inflammatory bowel disease on immunosuppressive therapy].
abstract: BACKGROUND
  Inactivated influenza vaccination is recommended yearly for patients with inflammatory bowel disease on immunosuppressive therapy.
  
  
  OBJECTIVE
  The aim of our study was to evaluate the immune response to seasonal influenza vaccination in patients with inflammatory bowel disease treated with immunosuppressants.
  
  
  METHODS
  Thirty patients were enrolled in this prospective study. Each patient was diagnosed with inflammatory bowel disease and treated with immunosuppressants. Blood samples were obtained from patients before and one month after influenza vaccination (A/California/7/2009(H1N1), A/Perth/16/2009(H3N2) B/Brisbane/60/2008) to assess the pre-and postimmunization antibody titers. Virus-specific antibodies were measured by ELISA.
  
  
  RESULTS
  The vaccine acceptance rate was 53.3%. Local adverse effect occurred in 5 patients. Seven patients developed systemic adverse events. Influenza-like symptoms occurred in 2 patients, although their antibody titers failed to increase significantly. Antibodies to influenza viruses were detected in each patient before the vaccination.
  
  
  CONCLUSIONS
  The results confirmed that each patient had appropriate antibody titer as correlation of protection even before the immunisation. Seroprotection rates were not influenced by the vaccination. The vaccine seemed to be safe.
authors.affiliation: Szegedi Tudományegyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Szeged Korányi. farkas.klaudia@gmail.com
authors.forename: Klaudia
authors.initials: K
authors.lastname: Farkas
authors.forename: Gabriella
authors.initials: G
authors.lastname: Terhes
authors.forename: Judit
authors.initials: J
authors.lastname: Deák
authors.forename: Anita
authors.initials: A
authors.lastname: Bálint
authors.forename: Ferenc
authors.initials: F
authors.lastname: Nagy
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szepes
authors.forename: Tibor
authors.initials: T
authors.lastname: Wittmann
authors.forename: Tamás
authors.initials: T
authors.lastname: Molnár
mesh_terms: D000293:Adolescent; D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000276:immunology; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D007166:Immunosuppressive Agents; D007252:Influenza Vaccines